MD
MDXH.US MDxHealth SA
- Market cap
- USD 13.7M
- P/E
- -
- P/B
- 23.64x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MDXH.US undervalued?
Graham numberThe Graham number of MDxHealth SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MDxHealth SA fundamental analysis
No fundamental analysis for MDxHealth SA yet.
MDxHealth SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary trac…
Full company profileMDxHealth SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MDxHealth SA annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 29.9M | 40.5M | 28.3M | 11.8M | 18.5M | 22.2M | 37.1M | 70.2M | 90.0M | 108M | 139M |
| Gross Profit | 19.8M | 30.3M | 16.7M | -144K | 8.04M | 10.6M | 19.2M | 43.9M | 55.1M | 64.4M | 81.6M |
| Operating Income | -12.8M | -12.3M | -32.1M | -43.2M | -27.1M | -26.8M | -37.9M | -27.3M | -24.7M | -15.4M | -33.1M |
| EBITDA | -11.6M | -10.2M | -29.5M | -39.7M | -24.0M | -24.1M | -36.4M | -30.5M | -22.0M | -14.0M | -17.1M |
| Net Income | -13.2M | -12.3M | -32.5M | -43.1M | -28.7M | -29.0M | -44.0M | -43.1M | -38.1M | -33.5M | -59.5M |
| EPS | -2.86 | -2.46 | -5.63 | -6.89 | -3.44 | -2.38 | -2.78 | -1.66 | -0.78 | -0.67 | -0.62 |
| Balance Sheet | |||||||||||
| Total Assets | 67.7M | 58.5M | 65.5M | 40.6M | 31.9M | 75.1M | 119M | 129M | 157M | 148M | 140M |
| Total Liabilities | 15.0M | 15.0M | 13.4M | 20.9M | 26.0M | 28.2M | 110M | 122M | 142M | 160M | 164M |
| Shareholders' Equity | 52.7M | 43.5M | 52.1M | 19.7M | 5.85M | 46.9M | 9.32M | 7.21M | 14.8M | -12.1M | -24.5M |
| Cash & Short-term Investments | 30.5M | 16.8M | 26.2M | 22.1M | 16.0M | 58.6M | 15.6M | 22.4M | 46.8M | 29.0M | 31.7M |
| Total Debt | 538K | 884K | 526K | 11.0M | 15.9M | 15.6M | 39.8M | 41.3M | 60.1M | 95.1M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.6M | -10.5M | -28.5M | -22.3M | -20.2M | -22.5M | -34.1M | -21.5M | -18.5M | -10.4M | -11.6M |
| Capital Expenditure | 4.89M | 4.86M | 1.35M | 73.0K | 537K | 896K | 4.16M | 5.02M | 2.16M | 1.16M | 536K |
| Free Cash Flow | -21.5M | -15.3M | -29.9M | -22.4M | -20.8M | -23.4M | -38.3M | -26.5M | -20.7M | -11.6M | -12.1M |
| Ratios | |||||||||||
| ROE | -25.0% | -28.2% | -62.3% | -218.5% | -490.0% | -61.8% | -472.8% | -597.9% | -256.5% | - | - |
| ROA | -19.5% | -21.0% | -49.6% | -106.1% | -90.0% | -38.6% | -37.0% | -33.4% | -24.2% | -22.7% | -42.5% |
| Net Profit Margin | -44.1% | -30.3% | -114.5% | -365.7% | -155.3% | -130.4% | -118.9% | -61.4% | -42.3% | -31.1% | -42.7% |
| Debt to Equity | 0.01x | 0.02x | 0.01x | 0.56x | 2.71x | 0.33x | 4.27x | 5.72x | 4.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MDxHealth SA dividends
MDxHealth SA has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Nov 14, 2023.
Who owns MDxHealth SA
- Insiders 22.15%
- Institutions 47.27%
- Public & others 30.58%
- Shares outstanding 95.4M
- Free float 62.3M
Top funds holding MDXH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Hood River Small/Mid-Cap Growth | 154K | 0.57% | -24.45% | Sep 2023 |
| Hood River Small/Mid Cap Gr CITFounder's | 154K | 0.57% | -2.62% | Sep 2023 |
| Pleiades Small Cap Equity A | 84.5K | 0.31% | -21.96% | Sep 2023 |
| Hood River International Opp Instl | 45.4K | 0.17% | +81.60% | Sep 2023 |
| Perkins Discovery | 35.0K | 0.13% | 0.00% | Sep 2023 |
| Fidelity® NASDAQ Composite Index® | 2.88K | 0.01% | 0.00% | Oct 2023 |
Top institutions holding MDXH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Rhumbline Advisers | 0.00 | 0.00% | -100.00% | Mar 2026 |
MDxHealth SA company profile
- Company name
- MDxHealth SA
- Ticker
- MDXH.US
- ISIN
- BE0974461940
- Exchange
- USA Stocks
- Listed since
- Nov 4, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 364
- Fiscal year end
- December
- Address
- CAP Business Center, Herstal, Belgium, 4040
- Phone
- 866 259 5644
- Website
- mdxhealth.com
About MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDxHealth SA management
6- Mr. Michael K. McGarrityCEO & Executive Director · born 1963
- Mr. Ron Kalfus CPAInterim Chief Financial Officer · born 1974
- Mr. Joseph Sollee J.D., LLMExecutive VP of Corporate Development & General Counsel · born 1965
- Mr. John A. BellanoChief Commercial Officer · born 1969
- Mr. Scott McMahanVice President of Finance & Accounting
- Ms. Kim LerouxExecutive Vice President of Revenue Cycle Management